Will Earnings Beat Estimates? Intra-Cellular Therapies Inc (ITCI) Stock
Robert W. Baird raised the price target for the Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock to “an Outperform”. The rating was released on January 03, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $80. The stock was downgraded by Goldman, who disclosed […]
Invest in Intra-Cellular Therapies Inc (ITCI) Stock with the prospect of future returns
Robert W. Baird raised the price target for the Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock to “an Outperform”. The rating was released on January 03, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $80. The stock was downgraded by Goldman, who disclosed […]
Intra-Cellular Therapies Inc (ITCI) Stock offers help to cash-strapped investors
Robert W. Baird raised the price target for the Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock to “an Outperform”. The rating was released on January 03, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $80. The stock was downgraded by Goldman, who disclosed […]
Why Intra-Cellular Therapies Inc (NASDAQ:ITCI) Stock Increased 0.97 percent in recent Trade?
Robert W. Baird raised the price target for the Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock to “an Outperform”. The rating was released on January 03, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $80. The stock was downgraded by Goldman, who disclosed […]
The Underside Of Intra-Cellular Therapies Inc (ITCI) Stock Is A Little Uncertain
Robert W. Baird raised the price target for the Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock to “an Outperform”. The rating was released on January 03, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $80. The stock was downgraded by Goldman, who disclosed […]